Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon

• US 7,125,703 B2
• Filed: 03/13/2002
• Issued: 10/24/2006
• Est. Priority Date: 03/13/2001
• Status: Expired due to Fees

• Current Assignee: Dendreon Pharmaceuticals, Inc. (Ya Fei Yuan,)
• Original Assignee: Dendreon Corporation (Bausch Health Cos., Inc.)
• Inventors: Madison, Edwin L., Ong, Edgar O.
• Primary Examiner(s): Nashed, Nashaat T.
• Assistant Examiner(s): Moore, William W.
• Application Number:
  US10/099,700
• Publication Number:
  US 20030008372A1
• Time in Patent Office: 1,686 Days
• Field of Search: 435/226, 435/69.1, 435/471, 435/23, 435/222, 536/23.2
• US Class Current: 435/226
• CPC Class Codes: C12N 9/6424 Serine endopeptidases (3.4.21)
• CPC Class Codes: Y10S 436/809 Multifield plates or multicontainer arrays

Abstract

Provided herein are type II transmembrane serine protease 7 (MTSP7) polypeptides. Zymogen and activated forms of these polypeptides as well as single and two chain forms of the protease domain are also provided. Methods using the polypeptides to identify compounds that modulate the protease activity of an MTSP7 are provided.

Claims

1. A substantially purified single or two chain MTSP7 protease that comprises the sequence of amino acids encoded by the sequence of nucleotides set forth in SEQ ID No. 15.

2. The protease of claim 1 that is an activated two chain protease.

5. The substantially purified protease of claim 1 that comprises the sequence of amino acids set forth in SEQ ID No. 16.

11. A conjugate comprising the protease of claim 1 or claim 4 and a targeting agent linked to the protease directly or via a linker.

12. The conjugate of claim 11, wherein the targeting agent permits affinity isolation or purification of the conjugate, attachment of the conjugate to a surface, detection of the conjugate, or targeted delivery of the conjugate to a selected tissue or cell.

17. A solid support, comprising two or more proteases of claim 1 or claim 4 linked thereto either directly or via a linker.

18. The support of claim 17, wherein the proteases comprise an array.

19. The support of claim 18, wherein the array further comprises a plurality of different protease domains.

20. A method for identifying compounds that inhibit the protease activity of the protease of claim 1 or claim 4, comprising:

contacting the protease of claim 1 or claim 4 with a substrate that is proteolytically cleaved by the protease, and, either simultaneously, before, or after, adding a test compound or plurality thereof;

measuring the amount of substrate cleaved in the presence of the test compound; and

,

selecting test compounds that decrease the amount of substrate cleaved compared to a control, thereby identifying compounds that inhibit the activity of the protease.

21. The method of claim 20, wherein the test compounds are small molecules, peptides, peptidomimetics, natural products, antibodies or fragments thereof that modulate the activity of the protease.

22. The method of claim 20, wherein a plurality of the test compounds are screened simultaneously.

23. The method of claim 20, wherein the change in the amount of substrate cleaved is assessed by comparing the amount of substrate cleaved in the presence of the test compound with the amount of substrate cleaved in the absence of the test compound.

24. The method of claim 22, wherein a plurality of the proteases are linked to a solid support, either directly or via a linker.

25. The method of claim 24, wherein the proteases comprise an array.

29. A method of identifying a compound that specifically binds to the protease of claim 1 or claim 4, comprising:

contacting the protease of claim 1 or claim 4 with a test compound or plurality thereof under conditions conducive to binding of the test compound to the protease;

measuring the amount of a test compound that remains bound to the protease; and

,

selecting test compounds that remain bound to the protease compared to a control, thereby identifying compounds that specifically bind to the protease.

30. The method of claim 29, wherein the protease is linked either directly or indirectly via a linker to a solid support.

31. The method of claim 29, wherein the test compounds are small molecules, peptides, peptidomimetics, natural products, antibodies or fragments thereof.

32. The method of claim 29, wherein a plurality of the test compounds are screened simultaneously.

33. The method of claim 29, wherein a plurality of the proteases are linked to a solid support.

35. A method for identifying activators of the zymogen form of the protease of claim 1 or claim 4, comprising:

contacting a zymogen form of the protease of claim 1 or claim 4 with a substrate of the activated form of the protease;

adding a test compound, wherein the test compound is added before, after, or simultaneously with the addition of the substrate; and

,

detecting cleavage of the substrate, thereby identifying compounds that activate the zymogen.

36. The method of claim 35, wherein the test compound is a small molecule, a nucleic acid or a polypeptide.

3. A substantially purified two chain protease comprising the MTSP7 protease domain encoded by the sequence of nucleotides set forth in SEQ ID No. 17.

13. A conjugate, comprising the protease of claim 3, and a targeting agent linked to the protease directly or via a linker.

14. The conjugate of claim 13, wherein the targeting agent permits affinity isolation or purification of the conjugate, attachment of the conjugate to a surface, detection of the conjugate, or targeted delivery of the conjugate to a selected tissue or cell.

26. A method for identifying compounds that inhibit the protease activity of the two-chain protease of claim 3, comprising:

contacting the two-chain protease of claim 3 with a substrate that is proteolytically cleaved by the protease, and, either simultaneously, before, or after, adding a test compound or plurality thereof;

measuring the amount of substrate cleaved in the presence of the test compound; and

,

selecting test compounds that decrease the amount of substrate cleaved compared to a control, thereby identifying compounds that inhibit the activity of the two-chain protease.

34. A method of identifying a compound that specifically binds to the two-chain protease of claim 3, comprising:

contacting the two-chain protease of claim 3 with a test compound or plurality thereof under conditions conducive to binding of the test compound to the protease;

measuring the amount of a test compound that remains bound to the protease; and

,

selecting test compounds that remain bound to the protease compared to a control, thereby identifying compounds that specifically bind to the protease.

4. A substantially purified single chain or two chain protease that consists of the MTSP7 protease domain encoded by the sequence of nucleotides set forth in SEQ ID No. 17.

6. The substantially purified protease of claim 4 that consists of the sequence of amino acids set forth in SEQ ID No. 18.

7. A modified single or two chain MTSP7 protease wherein the protease comprises the sequence of amino acids encoded by the sequence of nucleotides set forth in SEQ ID No. 15 modified by the replacement of a free Cysteine in the protease domain with another amino acid.

8. The protease of claim 7, wherein the replacing amino acid is a serine.

9. A modified protease, comprising the sequence of amino acids set forth between positions 206–

438 of SEQ ID No. 16 modified by the replacement of a free cysteine with a serine.

10. The protease of claim 9 that consists of the sequence of amino acids set forth between positions 206–

438 of SEQ ID No. 16 modified by the replacement of a free cysteine with a serine.

15. A conjugate comprising the protease of claim 9 and a targeting agent linked to the protease directly or via a linker.

16. A conjugate comprising the protease of claim 10 and a targeting agent linked to the protease directly or via a linker.

27. A method for identifying compounds that inhibit the protease activity of the protease of claim 9, comprising:

contacting the protease with a substrate that is proteolytically cleaved by the protease, and, either simultaneously, before, or after, adding a test compound or plurality thereof;

measuring the amount of substrate cleaved in the presence of the test compound; and

,

selecting test compounds that decrease the amount of substrate cleaved compared to a control, thereby identifying compounds that inhibit the activity of the protease.

28. A method for identifying compounds that inhibit the protease activity of the protease of claim 10, comprising:

contacting the protease with a substrate that is proteolytically cleaved by the protease, and, either simultaneously, before, or after, adding a test compound or plurality thereof;

measuring the amount of substrate cleaved in the presence of the test compound; and

,

selecting test compounds that decrease the amount of substrate cleaved compared to a control, thereby identifying compounds that inhibit the activity of the protease.